The transplanted liver began producing bile within two hours. Ten days later, it was still functioning when surgeons removed it—at the request of the recipient’s family.
The first milestone was biological. The second exposed a question that genetic engineering alone cannot answer: when medicine acquires the power to cross new boundaries, who decides how far it should go?
Six Gene Edits, Ten Days of Function
On March 26, 2025, researchers at Xijing Hospital in Xi’an, China, published detailed findings in Nature from an extraordinary operation performed a year earlier. Their subject was a 50-year-old man declared brain-dead after a severe head injury. Surgeons had connected the liver of a genetically modified Bama miniature pig to his bloodstream, leaving his original, functioning liver intact.
The procedure had been publicly reported in March 2024, but the new paper provided a detailed, peer-reviewed account of what happened during those ten days.
The donor pig carried six genetic modifications: three disabled genes responsible for cell-surface sugars that can provoke human immune rejection, while three introduced human proteins intended to protect the organ and regulate clotting. The surgery lasted more than ten hours.
The results offered measurable, if limited, encouragement. The pig liver secreted 66.5 milliliters of bile on the tenth postoperative day, and pig-derived albumin—a protein manufactured by liver cells—rose in the recipient’s blood. Tissue examinations found no signs of rejection, although doctors administered powerful immunosuppressants and recorded an initial decline in platelets. Peter Friend, a transplant surgeon at the University of Oxford, told The Guardian that the evidence of compatibility was encouraging.
But producing bile is different from replacing a human liver, which performs hundreds of interdependent functions. Because the recipient’s original liver remained healthy, the experiment could not establish whether a pig organ could sustain someone with liver failure. Researchers instead envision such organs providing temporary support until a patient's liver recovers or a human donor becomes available.
The field was already entering riskier territory: in May 2024, another Chinese surgical team transplanted a genetically modified pig liver into a living 71-year-old patient.
The Xijing researchers reported that six independent physicians confirmed brain death, four immediate family members signed informed consent, and multiple hospital committees—including one responsible for animal welfare—approved the experiment. When the family requested its termination on March 20, 2024, the researchers complied. The published account documents the family's authorization, but does not establish whether the man had previously expressed wishes about participating in research after death.
Scientific caution extends beyond organ rejection. Animal organs may carry infectious agents that screening cannot reliably exclude. Long-standing U.S. public-health guidance recommends lifelong surveillance of living xenotransplant recipients, recognizing risks that could extend to their close contacts. And an organ supply built from specially bred, genetically altered pigs raises questions about animal treatment that ethics approval alone cannot settle.
Making Room for Refusal in Transplant Medicine
For a generation watching once-speculative technologies enter ordinary medicine, the emerging dilemma is whether medical possibility will quietly become medical expectation.
A critically ill patient offered an experimental organ may have the formal right to refuse, yet few alternatives. A grieving family may be asked whether a loved one's body should serve research while still struggling to comprehend the loss.
Earlier interviews reveal that younger people approach this prospect with different instincts.
In focus-group research published in 2021, sociologist Gill Haddow documented conversations about hypothetical organ replacements. Amy, a participant in a university fencing group, said, “If it was a last resort, I would definitely accept an animal organ.” Yet she preferred a human organ when available and worried about immunosuppression.
Adila, participating in another university group, approached the question of identity differently: “I don't think it affects me as a person.” Both names were pseudonyms used in the published research. Neither participant was commenting on the Chinese experiment.
Their responses challenge the assumption that accepting a medical innovation necessarily means embracing every implication of it. Survival, bodily identity and uncertainty can carry different weights for different people.
In Haddow's accompanying survey of Scottish schoolchildren aged 11–17, fewer than 2% selected a pig organ as their preferred replacement. Many favored organs grown from their own cells. Those hypothetical preferences cannot predict what someone facing imminent death would decide. That distinction matters: a choice contemplated in a classroom can feel very different when presented at a hospital bedside.
For young people inheriting increasingly powerful biotechnology, meaningful consent must therefore extend beyond a technical explanation of surgical risks. It requires space for personal convictions, concerns about animal welfare, and the long-term obligations that treatment might impose. Most importantly, it requires preserving the freedom to decline without treating hesitation as ignorance or resistance to progress.
At Xijing Hospital, the experiment stopped while the transplanted organ still worked. The next ethical test is whether living patients will retain an equally meaningful power to say no when the stakes are their own survival.
Explore more exclusive insights at nextfin.ai.
